You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

McKinsey
Medtronic
Express Scripts
Mallinckrodt
Colorcon
Dow

Last Updated: February 28, 2020

DrugPatentWatch Database Preview

Litigation Details for Salix Pharmaceuticals Inc. v. Lupin Limited (D. Del. 2012)


Email this page to a colleague

See Plans and Pricing

« Back to Dashboard

Salix Pharmaceuticals Inc. v. Lupin Limited (D. Del. 2012)

Docket   Start Trial Date Filed 2012-09-07
Court District Court, D. Delaware Date Terminated 2014-09-16
Cause 35:271 Patent Infringement Assigned To Gregory Moneta Sleet
Jury Demand Defendant Referred To
Parties DR. FALK PHARMA GMBH; LUPIN LIMITED; LUPIN PHARMACEUTICALS INC.; SALIX PHARMACEUTICALS INC.
Patents 6,551,620; 8,337,886; 8,496,965
Attorneys Carl B. Massey; Damon Gupta; Dana C. Mahadeo; Dana Kathryn Severance; Daniel Marcus Attaway; John C. Phillips , Jr.; John D. Polivick; Kristen Healey Cramer; Mary W. Bourke; Megan C. Haney; Paul J. Molino; Peter J. Curtin; Ryan M. Daniel; Tara M. Raghavan; Thomas F. Poche; Tryn T. Stimart; William A. Rakoczy; William Ward
Link to Docket External link to docket
Small Molecule Drugs cited in Salix Pharmaceuticals Inc. v. Lupin Limited
The small molecule drug covered by the patents cited in this case is   Start Trial .

Details for Salix Pharmaceuticals Inc. v. Lupin Limited (D. Del. 2012)

Date Filed Document No. Description Snippet Link To Document
0000-00-00 1 Complaint the owner by assignment of U.S. Patent No. 6,551,620 (“the ’620 patent”), entitled “Pellet Formulation…expiration of United States Patent No. 6,551,620 were acts of infringement of the patent-in-suit; D. …declaration that the claims of United States Patent No. 6,551,620 are valid and enforceable. B. … before the expiration of United States Patent No. 6,551,620 was an act of infringement; …infringe one or more claims of United States Patent No. 6,551,620 under one or more of 35 U.S.C. §§ 271(a) External link to document
0000-00-00 118 Order ORDER Construing the Terms of U.S. Patent Nos. 6,551,620; 7,547,451; 8,337,886; and 8,496,965. Signed… 16 September 2014 1:12-cv-01104 830 Patent Defendant District Court, D. External link to document
0000-00-00 130 Notice of Service Regarding the Invalidity of Claim 30 of U.S. Patent No. 8,337,886 filed by Lupin Limited, Lupin Pharmaceuticals… 16 September 2014 1:12-cv-01104 830 Patent Defendant District Court, D. External link to document
0000-00-00 3 Patent/Trademark Report to Commissioner Commissioner of Patents and Trademarks for Patent/Trademark Number(s) U.S. 6,551,620. (eam) (Entered:… 16 September 2014 1:12-cv-01104 830 Patent Defendant District Court, D. External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Dow
AstraZeneca
Medtronic
Johnson and Johnson
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.